echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Advanced kidney cancer "immune and targeted" first-line treatment! The Opdivo-Cabometyx program was approved by the FDA and beats Sutt!

    Advanced kidney cancer "immune and targeted" first-line treatment! The Opdivo-Cabometyx program was approved by the FDA and beats Sutt!

    • Last Update: 2021-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Treatment of Renal Cell Carcinoma (RCC), Opdivo's approved adaptation is: (1) for previous use in Patients with advanced RCC who have been treated with anti-angiogenesis therapy; (2) patients with advanced RCC who are in the first line of treatment with Yervoy (ipilimumab, iplimma, anti-CTLA-4 monoantigen) are treated with medium- or high-risk advanced RCC.
    () Origin: U.S. Food and Drug Administration approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.